“Placebo-Controlled Trial of Pharmaceutical Optimized Hydralazine 25mg (F-6) in Patients With Essential Hypertension”. Medical Forum Monthly, vol. 30, no. 5, May 2024, https://medicalforummonthly.com/index.php/mfm/article/view/3666.